Drug Profile
Cediranib - AstraZeneca
Alternative Names: AZD-2171; Cediranib-maleate; Recentin; ZemfirzaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Cancer Research UK; Institute of Cancer Research; Mario Negri Institute for Pharmacological Research; Merck Sharp & Dohme; Myriad Genetic Laboratories; National Cancer Institute (Canada); National Cancer Institute (USA); Royal Marsden NHS Foundation Trust; University College London; University Health Network; University of London; University of Manchester; University of Oxford
- Class Antineoplastics; Ethers; Fluorinated hydrocarbons; Indoles; Pyrrolidines; Quinazolines; Small molecules
- Mechanism of Action Platelet-derived growth factor inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ovarian cancer
- Phase II Alveolar soft part sarcoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Malignant-mesothelioma; Peritoneal cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- No development reported Gynaecological cancer
- Discontinued Acute myeloid leukaemia; Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Soft tissue sarcoma
Most Recent Events
- 20 Oct 2023 Efficacy data of phase III trial in ovarian cancer was presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 01 Jul 2023 AstraZeneca completes the phase II COMICE trial in Cervical cancer (Combination therapy, Late-stage disease, Recurrent, Maintenance therapy, Second-line therapy or greater) in United Kingdom (PO) (ISRCTN10841582) (NCT04487587) (EudraCT2016-004215-13)
- 02 Jun 2023 Pharmacodynamics data from a phase II COMICE trial in Endometrial cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)